

Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.



2nd

HALF-YEARLY FINANCIAL REPORT FOR THE REPORTING PERIOD

2021

PERIOD END DATE

31/12/2021

I. IDENTIFICATION DETAILS

Corporate name: LABORATORIOS FARMACEUTICOS ROVI, S.A.

Registered address: c/ Julián Camarillo, 35, 28037 Madrid

Tax Id No. A-28041283

II. INFORMATION SUPPLEMENTING THE PERIODIC INFORMATION PUBLISHED PREVIOUSLY



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

1. INDIVIDUAL STATEMENT OF FINANCIAL POSITION (PREPARED USING NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

ASSETS		CURRENT PERIOD 31/12/2021	PREVIOUS PERIOD 31/12/2020
A) NON-CURRENT ASSETS	0040	131.457	141.497
1. Intangible assets:	0030	33.816	37.487
a) Goodwill	0031		
b) Other intangible assets	0032	33.816	37.487
2. Property, plant and equipment	0033	52.396	52.130
3. Investment property	0034		
4. Non-current investments in group and associated companies	0035	41.418	45.484
5. Non-current financial investments	0036	1.485	1.484
6. Deferred tax assets	0037	2.342	4.912
7. Other non-current assets	0038		
B) CURRENT ASSETS	0085	346.642	414.030
1. Non-current assets held for sale	0050		
2. Inventories	0055	105.784	74.677
3. Trade and other receivables	0060	202.206	305.206
a) Trade receivables for sales of goods and services	0061	185.745	292.992
b) Other receivables	0062	6.572	3.872
c) Current tax assets	0063	9.889	8.342
4. Current investments in group and associated companies	0064	312	
5. Current financial investments	0070		
6. Current accruals and prepayments	0071	376	3
7. Cash and cash equivalents	0072	37.964	34.144
TOTAL ASSETS (A+B)	0100	478.099	555.527



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

1. INDIVIDUAL FINANCIAL STATEMENTS (PREPARED USING THE NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

		CURRENT PERIOD 31/12/2021	PREVIOUS PERIOD 31/12/2020
A) EQUITY (A.1 + A.2 + A.3)	0195	339.631	330.686
A.1) EQUITY	0180	337.522	328.283
1. Capital:	0171	3.364	3.364
a) Authorized capital	0161	3.364	3.364
a) Less: uncalled capital	0162		
2. Share premium	0172	87.636	87.636
3. Reserves	0173	7.032	7.032
4. Less: treasury stock	0174	(66.121)	(20.185)
5. Retained earnings	0178	240.468	179.299
6. Other shareholder contributions	0179		
7. Profit or loss for period	0175	65.143	71.137
8. Less: interim dividend	0176		
9. Other equity instruments	0177		
A.2) ADJUSTMENTS FOR CHANGES IN VALUE	0188	(2)	(3)
1. Available-for-sale financial assets	0181	(2)	(3)
2. Hedging transactions	0182		
3. Other	0183		
A.3) GRANTS, DONATIONS AND LEGACIES RECEIVED	0194	2.111	2.406
B) NON-CURRENT LIABILITIES	0120	58.036	64.135
1. Non-current provisions	0115		
2. Non-current debt:	0116	52.298	53.647
a) Bank borrowings and debentures or other negotiable instruments	0131	44.107	44.825
b) Other financial liabilities	0132	8.191	8.822
3. Non-current debt with group and associated companies	0117		
4. Deferred tax liabilities	0118	4.278	4.700
5. Other non-current liabilities	0135		
6. Non-current accruals	0119	1.460	5.788
C) CURRENT LIABILITIES	0130	80.432	160.706
1. Liabilities associated with non-current assets held for sale	0121		
2. Current provisions	0122	9.430	15.741
3. Current debt:	0123	2.890	2.867
a) Bank borrowings and debentures or other negotiable instruments	0133	714	175
b) Other financial liabilities	0134	2.176	2.692
4. Current debt with group and associated companies	0129	290	184
5. Trade and other payables:	0124	67.036	140.834
a) Trade payables	0125	57.166	135.148
b) Other payables	0126	9.870	5.686
c) Current tax liabilities	0127		
6. Other current liabilities	0136		
7. Current accruals	0128	786	1.080
TOTAL EQUITY AND LIABILITIES (A + B + C)	0200	478.099	555.527



Dirección General de Mercad Edison, 4, 28006 Madrid, Espa (+34) 915 851 500, www.cnmv.

LABORATORIOS FARMACEUTICOS ROVI, S.

IV. SELECTED FINANCIAL INFORMATION

2. INDIVIDUAL INCOME STATEMENT (PREPARED USING THE NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

		CURRENT PERIOD (2nd HALF)	PREVIOUS PERIOD (2nd HALF)	ACCUMULATED PERIOD 31/12/2021	ACCUMULATED PREVIOUS PERIOD
(+) Net revenue	0205	275.059	238.953	509.920	459.424
(+/-) Change in inventories of finished products and work in progress	0206	3.255	(34.027)	19.298	(7.245)
(+) Work performed by the company on its assets	0207				
(-) Supplies	0208	(192.233)	(128.623)	(384.450)	(308.275)
(+) Other operating income	0209	4.843	3.060	6.948	5.111
(-) Employee benefit expenses	0217	(19.302)	(16.858)	(40.562)	(32.803)
(-) Other operating expenses	0210	(41.008)	(33.575)	(69.470)	(61.815)
(-) Amortization and depreciation charges	0211	(5.090)	(4.953)	(10.303)	(9.710)
(+) Allocation of grants for non-financial assets and other	0212	389	300	741	629
(+) Excess provisions	0213				
(+/-) Impairment and gains/(losses) on disposal of intangible assets and property, plant & equipment	0214	(120)	(56)	(120)	(70)
(+/-) Other gains/(losses)	0215				
= OPERATING PROFIT/(LOSS)	0245	25.793	24.221	32.002	45.246
(+) Finance income	0250	244	289	25.589	31.723
(-) Finance expenses	0251	(340)	(411)	(655)	(789)
(+/-) Change in fair value of financial instruments	0252	(96)	(1.330)	908	(796)
(+/-) Exchange rate differences	0254	(48)	58	(111)	77
(+/-) Impairment and gains/(losses) on disposal of financial instruments	0255	1.161	(511)	1.161	(245)
= FINANCE PROFIT/(LOSS)	0256	921	(1.905)	26.892	29.970
= PROFIT/(LOSS) BEFORE TAX	0265	26.714	22.316	58.894	75.216
(+/-) Corporate income tax	0270	4.998	(3.672)	6.249	(4.079)
= PROFIT/(LOSS) FOR PERIOD ON CONTINUING OPERATIONS	0280	31.712	18.644	65.143	71.137
(+/-) Profit/(loss) for perid on discontinued operations, net of tax	0285				
= PROFIT/(LOSS) FOR PERIOD	0300	31.712	18.644	65.143	71.137

EARNINGS PER SHARE		Amount (X.XX euros)	Amount (X.XX euros)	Amount (X.XX euros)	Amount (X.XX euros)	
Basic	0290	0,58	0,33	1,18	1,28	
Diluted	0295					



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION 3. INDIVIDUAL STATEMENT OF CHANGES IN EQUITY A. INDIVIDUAL STATEMENT OF RECOGNIZED INCOME AND EXPENSES (PREPARED USING THE NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

		CURRENT PERIOD 31/12/2021	PREVIOUS PERIOD 31/12/2020
A) PROFIT/(LOSS) FOR PERIOD (from Income Statement)	0305	65.143	71.137
B) INCOME OR EXPENSES CREDITED OR CHARGED DIRECTLY TO EQUITY:	0310	700	514
1. Measurement of financial instruments	0320	1	
a) Available-for-sale financial assets	0321	1	
b) Other income /(expenses)	0323		
2. Cash flow hedges	0330		
3. Grants, donations and legacies received	0340	933	686
4. Actuarial gains and losses and other adjustments	0344		
5. Other income or expenses credited or charged directly to equity	0343		
6. Tax effect	0345	(234)	(172)
C) TRANSFERS TO PROFIT AND LOSS:	0350	(994)	(858)
1. Measurement of financial instruments	0355		
a) Available-for-sale financial assets	0356		
b) Other income /(expenses)	0358		
2. Cash flow hedges	0360		
3. Grants, donations and legacies received	0366	(1.326)	(1.145)
4. Other income or expenses credited or charged directly to equity	0365		
5. Tax effect	0370	332	287
TOTAL RECOGNIZED INCOME/(EXPENSES) (A+B+C)	0400	64.849	70.793



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

Т

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

3. INDIVIDUAL STATEMENT OF CHANGES IN EQUITY B. INDIVIDUAL STATEMENT OF CHANGES IN TOTAL EQUITY (1/2) (PREPARED USING THE NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

_ ..

Units: thousands of euros

				Equity					
CURRENT PERIOD		Share capital	Share premium and reserves	Treasury stock	Profit/ (loss) for the period	Other equity instru- ments	Adjust- ments for changes in value	Grants, donations and legacies received	Total equity
Closing balance at 01/01/2021	3010	3.364	273.967	(20.185)	71.137		(3)	2.406	330.686
Adjustments for changes in accounting policies	3011								
Adjustments for errors	3012								
Adjusted opening balance	3015	3.364	273.967	(20.185)	71.137		(3)	2.406	330.686
I. Total recognized income/(expenses)	3020				65.143		1	(295)	64.849
II. Transactions with shareholders or owners	3025		10.882	(45.936)	(21.132)				(56.186)
1. Capital increases/(reductions)	3026								
2. Conversion of financial liabilities to equity	3027								
 Distribution of dividends 	3028				(21.132)				(21.132)
4. Treasury stock transactions (net)	3029		10.882	(47.339)					(36.457)
5.Increases/(reductions) due to business combinations	3030								
 Other transactions with shareholders or owners 	3032			1.403					1.403
III. Other equity transactions	3035		50.287		(50.005)				282
1. Payments based on equity instruments	3036								
2. Transfers between equity items	3037		50.005		(50.005)				
3. Other changes	3038		282						282
Closing balance at 31/12/2021	3040	3.364	335.136	(66.121)	65.143		(2)	2.111	339.631



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

3. INDIVIDUAL STATEMENT OF CHANGES IN EQUITY B. INDIVIDUAL STATEMENT OF CHANGES IN TOTAL EQUITY (2/2) (PREPARED USING THE NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

				Equity					
PREVIOUS PERIOD		Share capital	Share premium and reserves	Treasury stock	Profit/ (loss) for the period	Other equity instrume nts	Adjustment s for changes in value	Grants, donations and legacies received	Total equity
Closing balance at 01/01/2020 (comparative period)	3050	3.364	248.006	(10.341)	25.553		(3)	2.750	269.329
Adjustments for changes in accounting policies	3051								
Adjustments for errors	3052								
Adjusted opening balance (comparative period)	3055	3.364	248.006	(10.341)	25.553		(3)	2.750	269.329
I. Total recognized income/(expenses)	3060				71.137			(344)	70.793
II. Transactions with shareholders or owners	3065		10.077	(9.844)	(9.700)				(9.467)
1. Capital increases/(reductions)	3066								
2. Conversion of financial liabilities to equity	3067								
3. Distribution of dividends	3068				(9.700)				(9.700)
4. Treasury stock transactions (net)	3069		10.077	(9.844)					233
5.Increases/ (reductions) due to business combinations	3070								
 Other transactions with shareholders or owners 	3072								
III. Other equity transactions	3075		15.884		(15.853)				31
1. Payments based on equity instruments	3076								
2. Transfers between equity items	3077		15.853		(15.853)				
3. Other changes	3078		31						31
Closing balance at 31/12/2020 (comparative period)	3080	3.364	273.967	(20.185)	71.137		(3)	2.406	330.686



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

4. INDIVIDUAL STATEMENT OF CASH FLOWS (PREPARED USING NATIONAL ACCOUNTING STANDARDS CURRENTLY IN FORCE)

Units: thousands of euros	I	CURRENT	DDEVIOUS
		CURRENT PERIOD 31/12/2021	PREVIOUS PERIOD 31/12/2020
A) CASH FLOWS FROM OPERATING ACTIVITIES (1+2+3+4)	0435	64.680	13.905
1.Profit/(loss) before tax	0405	58.894	75.216
2. Adjustments to profit/(loss)	0410	61	12.953
(+) Amortization and depreciation of intangible assets and property, plant and equipment	0411	10.303	9.710
(+/-) Other adjustments to profit/(loss) (net)	0412	(10.242)	3.243
3. Changes in working capital	0415	27.901	(69.633)
4. Other cash flows from operating activities:	0420	(22.176)	(4.631)
(-) Payment of interest	0421	- /	()
(+) Proceeds from dividends	0422		
(+) Proceeds from interest	0423		
(+/-) Proceeds from/(payments for) corporate income tax	0430	(22.694)	(5.884)
(+/-) Other proceeds from/(payments for) operating activities	0425	518	1.253
B) CASH FLOWS FROM INVESTING ACTIVITIES (1+2)	0460	(8.254)	(10.261)
1. Payments of investments:	0440	(7.034)	(11.074)
(-) Group companies, associates and business units	0441		· · · · · · · · · · · · · · · · · · ·
(-) Property, plant and equipment, intangible assets and investment property	0442	(7.034)	(11.074)
(-) Other financial assets	0443		· · · · · · · · · · · · · · · · · · ·
(-) Non-current assets and liabilities classified as held for sale	0459		
(-) Other assets	0444		
2. Proceeds from disinvestments	0450	(1.220)	813
(+) Group companies, associates and business units	0451	(1.775)	144
(+) Property, plant and equipment, intangible assets and investment property	0452	41	20
(+) Other financial assets	0453		
(+) Non-current assets and liabilities classified as held for sale	0461		
(+) Other assets	0454	514	649
C) CASH FLOWS FROM FINANCING ACTIVITIES (1+2+3)	0490	(52.606)	(20.817)
1. Proceeds from and (payments for) equity instruments:	0470	(36.457)	233
(+) Issue	0471		
(-) Amortization	0472		
(-) Acquisition	0473	(78.785)	(37.255)
(+) Disposal	0474	42.328	37.488
(+) Grants, donations and legacies received	0475		
2. Proceeds from and (payments for) financial liability instruments:	0480	4.983	(11.350)
(+) Issue	0481	1.340	1.430
(-) Repayment and amortization	0482	3.643	(12.780)
3. Payment of dividends and remuneration of other equity instruments	0485	(21.132)	(9.700)
D) EFFECT OF EXCHANGE RATE CHANGES	0492		
E) NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS (A+B+C+	0495	3.820	(17.173)
F) CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	0499	34.144	51.317
G) CASH AND CASH EQUIVALENTS AT END OF PERIOD (E+F)	0500	37.964	34.144

COMPONENTS OF CASH AND CASH EQUIVALENTS AT END OF PERIOD		CURRENT PERIOD 31/12/2021	PREVIOUS PERIOD 31/12/2020
(+) Cash in hand and at bank	0550	37.964	34.144
(+) Other financial assets	0552		
(-) Less: bank overdrafts repayable on demand	0553		
TOTAL CASH AND CASH EQUIVALENTS AT END OF PERIOD	0600	37.964	34.144



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

5. CONSOLIDATED STATEMENT OF FINANCIAL POSITION (UNDER IFRS ADOPTED) (1/2)

ASSETS		CURRENT PERIOD 31/12/2021	PREVIOUS PERIOD 31/12/2020
A) NON-CURRENT ASSETS	1040	226.314	209.861
1. Intangible assets:	1030	38.558	41.413
a) Goodwill	1031		
b) Other intangible assets	1032	38.558	41.413
2. Property, plant and equipment	1033	181.775	155.395
3. Investment property	1034		
4. Investments in group and associated companies accounted for using the equity me	1035	1.994	1.812
5. Non-current financial investments	1036	72	71
a) At fair value through profit or loss	1047	72	71
Of which, "Designated upon initial recognition"	1041		
b) At fair value through other comprehensive income	1042		
Of which, "Designated upon initial recognition"	1043		
c) At amortised cost	1044		
6. Non-current derivatives	1039		
a) Hedging instruments	1045		
b) Other	1046		
7. Deferred tax assets	1037	3.850	11.105
8. Other non-current assets	1038	65	65
B) CURRENT ASSETS	1085	506.362	364.578
1. Non-current assets held for sale	1050		
2. Inventories	1055	245.473	227.199
3. Trade and other receivables	1060	160.063	84.204
a) Trade receivables for sale of goods and services	1061	129.801	63.285
b) Other receivables	1062	20.371	13.116
c) Current tax assets	1063	9.891	7.803
4. Current financial assets	1070		
a) At fair value through profit or loss	1080		
Of which, "Designated upon initial recognition"	1081		
b) At fair value through other comprehensive income	1082		
Of which, "Designated upon initial recognition"	1083		
c) At amortised cost	1084		
5.Current derivatives	1076		
a) Hedging instruments	1077		
b) Other	1078		
6. Other current assets	1075	1.791	13
7. Cash and cash equivalents	1072	99.035	53.162
TOTAL ASSETS (A+B)	1100	732.676	574.439



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

5. CONSOLIDATED STATEMENT OF FINANCIAL POSITION (UNDER IFRS ADOPTED) (2/2)

Units: thousands of euros LIABILITIES AND EQUITY		CURRENT PERIOD 31/12/2021	PREVIOUS PERIOD 31/12/2020
A) EQUITY (A.1 + A.2 + A.3)	1195	470.976	373.700
A.1) EQUITY	1180	470.978	373.703
1. Capital:	1171	3.364	3.364
a) Authorized capital	1161	3.364	3.364
b) Less: uncalled capital	1162		
2. Share premium	1172	87.636	87.636
3. Reserves	1173	673	673
4. Less treasury stock	1174	(66.121)	(20.185)
5. Retained earnings	1178	292.349	241.158
6. Other shareholder contributions	1179		
7. Profit or loss for period	1175	153.077	61.057
8. Less: interim dividend	1176		
9. Other equity instruments	1177		
A.2) ACCUMULATED OTHER COMPREHENSIVE INCOME	1188	(2)	(3)
1. Items not reclassified to profit and loss for the period	1186	(-)	(-)
a) Equity instruments held at fair value through other comprehensive income	1185		
b) Other	1190		
2. Items that may be reclassified to profit and loss for the period	1187	(2)	(3)
a) Hedging transactions	1182	(=/	(0)
b) Hedging differences	1184		
c) Share in other comprehensive income of joint ventures and other	1192		
d) Debt instruments held at fair value through other comprehensive income	1191		
e) Other	1183	(2)	(3)
EQUITY ATTRIBUTED TO PARENT COMPANY (A.1 + A.2)	1189	470.976	373.700
A.3) NON-CONTROLLING INTERESTS	1193	470.570	575.700
B) NON-CURRENT ASSETS	1120	71.312	77.850
1. Grants	1117	71.012	11.000
2. Non-current provisions	1115		
3. Non-current financial liabilities:	1116	66.745	68.421
a) Bank borrowings and debentures or other negotiable securities	1131	44.107	44.825
b) Other financial liabilities	1132	22.638	23.596
4. Deferred tax liabilities	1118	776	929
5. Non-current derivatives	1140	110	020
a) Hedging instruments	1140		
b) Other	1141		
6. Other non-current liabilities	1135	3.791	8.500
C) CURRENT LIABILITIES	1130	190.388	122.889
1. Liabilities related to current assets held for sale	1121	100.000	122.000
2. Current provisions	1121		
3. Current finanacial liabilities:	1122	6.400	5.097
a) Bank borrowings and debentures or other negotiable securities	1123	714	175
b) Other financial liabilities	1133	5.686	4.922
4. Trade and other payables:	1134	125.854	91.364
a) Trade payables	1124	97.407	63.452
, , , , , , , , , , , , , , , , , , , ,	1125	27.766	27.912
b) Other payables c) Current tax liabilities	1126	681	21.912
	_	17	925
5. Current derivatives	1145 1146	17	925
a) Hedging instruments	1146 1147	17	925
b) ()thor	1 14/		
b) Other 5. Other current liabilities	1136	58.117	25.503



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION 6. CONSOLIDATED INCOME STATEMENT (UNDER IFRS ADOPTED)

Units: thousands of euros		CURRENT PERIOD (2nd HALF)	PREVIOUS PERIOD (2nd HALF)	ACCUMULA TED PERIOD 31/12/2021	ACCUMULAT ED PREVIOUS PERIOD 31/12/2020
(+) Net revenue	1205	358.627	228.832	648.677	419.961
(+/-) Change in inventories of finished products and work in progress	1206	345	(19.176)	782	17.659
(+) Work performed by the company on its assets	1207				
(-) Supplies	1208	(127.902)	(80.073)	(264.637)	(196.311)
(+) Other operating income	1209				
(-) Employee benefit expenses	1217	(45.093)	(37.877)	(89.803)	(74.429)
(-) Other operating expenses	1210	(57.786)	(40.363)	(93.502)	(73.706)
(-) Amortization and depreciation charges	1211	(10.692)	(10.052)	(21.364)	(19.593)
(+) Allocation of grants for non-financial assets and other	1212	748	556	1.334	1.157
(+/-) Impairment of intangible assets and property, plant & equipment	1214	(95)	(56)	(95)	(56)
(+/-) Gains/(losses) on disposal of intangible assets and property, plant & equipment	1216				
(+/-) Other gains/(losses)	1215				
= OPERATING PROFIT/(LOSS)	1245	118.152	41.791	181.392	74.682
(+) Finance income	1250	3	2	68	4
a) Interest income calculated using the effective interest rate method	1262	3	2	68	4
b) Other	1263				
(-) Finance expenses	1251	(449)	(221)	(905)	(1.072)
(+/-) Change in fair value of financial instruments	1252	(96)	(1.330)	908	(796)
(+/-) Gains/(losses) due to the reclassification of financial		(00)	(11000)		(100)
assets held at amortised cost to financial assets held at fair	1258				
value					
(+/-) Gains/(losses) due to the reclasification of financial assets held at fair value through other comprehensive income to financial assets held at fair value	1259				
(+/-) Exchange rate differences	1254	(104)	18	(178)	39
(+/-) Impairment on disposal of financial instruments	1255				
(+/-) Gains/(losses) on disposal of financial instruments	1257	1.161	(511)	1.161	(245)
a) Financial instruments at amortised cost	1260				
b) Rest of financial instruments	1261	1.161	(511)	1.161	(245)
= FINANCE PROFIT/(LOSS)	1256	515	(2.042)	1.054	(2.070)
(+/-) Profit/(loss) of entities measured using the equity method	1253	52	(9)	182	(31)
= PROFIT/(LOSS) BEFORE TAX	1265	118.719	39.740	182.628	72.581
(+/-) Corporate income tax	1270	(16.665)	(8.276)	(29.551)	(11.524)
= PROFIT/(LOSS) FOR PERIOD FROM CONTINUING OPERATIONS	1280	102.054	31.464	153.077	61.057
(+/-)Profit/(loss) for period from discontinued operations, net of taxes	1285				
= CONSOLIDATED PROFIT/(LOSS) FOR PERIOD	1288	102.054	31.464	153.077	61.057
a) Profit/(loss) attributed to parent company	1300	102.054	31.464	153.077	61.057
b) Profit/(loss) attributed to non-controlling interests	1289				

EARNINGS PER SHARE		AMOUNT (X.XX euros)	AMOUNT (X.XX euros)	AMOUNT (X.XX euros)	AMOUNT (X.XX euros)
Basic	1290	1,84	0,57	2,76	1,10
Diluted	1295				



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

7. CONSOLIDATED STATEMENT OF RECOGNIZED INCOME AND EXPENSES (UNDER IFRS ADOPTED)

Units: thousands of euros		CURRENT PERIOD (2nd HALF)	. ,	CURRENT PERIOD 31/12/2021	PREVIOUS PERIOD 31/12/2020
A) PROFIT/(LOSS) FOR PERIOD (from Income Statement)	1305	102.054	31.464	153.077	61.057
B) OTHER COMPREHENSIVE INCOME - ITEMS NOT					
RECLASSIFIED TO PROFIT AND LOSS FOR THE PERIOD	1310				
1. Remeasurement (reversal of remeasurement) of property, plant	4044				
and equipment and intangible assets	1311				
2. Actuarial gains and losses	1344				
3. Share in other recognized comprehensive income from	40.40				
investments in joint ventures and associates	<u>1342</u> 1346				
 Equity instruments held at fair value through other Other income and expenses not reclassified to profit and loss for 	1340				
the period	1343				
6. Tax effect	1345				
C) OTHER COMPREHENSIVE INCOME - ITEMS THAT MAY	1343				
SUBSEQUENTLY BE RECLASSFIED TO PROFIT AND LOSS FOR	1350	-	-	1	0
1. Hedging transactions:	1360				
a) Gains/(losses) on remeasurement	1361				
b) Amounts transferred to profit and loss	1362				
c) Amounts transferred at initial value of hedged items	1363				
d) Other reclassifications	1364				
2. Conversion differences:	1365				
a) Gains/(losses) on remeasurement	1366				
b) Amounts transferred to profit and loss	1367				
c) Other reclassifications	1368				
3. Share in other recognized comprehensive income from					
investments in joint ventures and associates	1370				
a) Gains/(losses) from measurement	1371				
b) Amounts transferred to profit and loss	1372				
c) Other reclassifications	1373				
4. Debt instruments held at fair value through other comprehensive					
income:	1381				
a) Gains/(losses) on remeasurement	1382				
b) Amounts transferred to profit and loss	1383				
c) Other reclassifications	1384				
5. Other comprehensive income and expenses that may					
subsequently be reclassified to profit and loss for the period:	1375			1	
a) Gains/(losses) on remeasurement	1376	-		1	
b) Amounts transferred to profit and loss	1377				
c) Other reclassifications	1978				
6. Tax effect	1380				
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (A+B+C)	1400	102.054	31.464	153.078	61.057
a) Attributed to parent company	1398	102.054	31.464	153.078	61.057
b) Attributed to parchi company b) Attributed to non-controlling interests	1399	102.004	01.404	100.070	01.007



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

8. CONSOLIDATED STATEMENT OF CHANGES IN TOTAL EQUITY (UNDER IFRS ADOPTED) (1/2)

			Equit						
		Equity							
CURRENT PERIOD		Share capital	Share premium and reserves	Treasury stock	Profit/ (loss) for the per. attributed to parent company	Other equity instru- ments	Adjust- ments for changes in value	Non- controlling interests	Total equity
Closing balance at 01/01/2021	3110	3.364	329.467	(20.185)	61.057		(3)		373.700
Adjustments for changes in accounting policies	3111								
Adjustments for errors	3112								
Adjusted opening balance	3115	3.364	329.467	(20.185)	61.057		(3)		373.700
I. Total recognized	3120				153.077		1		153.078
income/(expenses)									
shareholders or owners	3125		10.882	(45.936)	(21.132)				(56.186)
1. Capital increases/(reductions)	3126								
2. Conversion of financial liabilities to equity	3127								
3. Distribution of dividends	3128				(21.132)				(21.132)
4. Treasury stock transactions (net)	3129		10.882	(45.936)					(35.054)
5.Increases/(reductions) due to business combinations	3130								
6. Other transactions with shareholders or owners	3132								
III. Other equity transactions	3135		40.309		(39.925)				384
1. Payments based on equity instruments	3136								
2. Transfers between equity items	3137		39.925		(39.925)				
3. Other changes	3138		384						384
Closing balance at 31/12/2021	3140	3.364	380.658	(66.121)	153.077		(2)		470.976



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

8. CONSOLIDATED STATEMENT OF CHANGES IN TOTAL EQUITY (UNDER IFRS ADOPTED) (2/2)

		Equity attributed to parent company							
				Equity					
PREVIOUS PERIOD		Share capital	Share premium and reserves	Treasury stock	Profit/ (loss) for the per. attributed to parent company	Other equity instru- ments	Adjust- ments for changes in value	Non- controlling interests	Total equity
Closing balance at 01/01/2020 (comparative	3150	3.364	290.093	(10.341)	39.273		(3)		322.386
period) Adjustments for changes in	3151								
accounting policies Adjustments for errors	3152								
Adjusted opening balance	3155	3.364	290.093	(10.341)	39.273		(3)		322.386
I. Total recognized income/(expenses)	3160				61.057				61.057
II. Transactions with shareholders or owners	3165		10.077	(9.844)	(9.700)				(9.467)
1. Capital increases/(reductions)	3166								
2. Conversion of financial liabilities to equity	3167								
3. Distribution of dividends	3168				(9.700)				(9.700)
4. Treasury stock transactions (net)	3169		10.077	(9.844)					233
5.Increases/(reductions) due to business combinations	3170								
6. Other transactions with shareholders or owners	3172								
III. Other equity transactions	3175		29.297		(29.573)				(276)
1. Payments based on equity instruments	3176								
2. Transfers between equity items	3177		29.573		(29.573)				
3. Other changes	3178		(276)						(276)
Closing balance at 31/12/2020 (comparative period)	3180	3.364	329.467	(20.185)	61.057		(3)		373.700



(-) Less: bank overdrafts repayable on demand

TOTAL CASH AND CASH EQUIVALENTS AT END OF PERIOD

Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION

9.A. CONSOLIDATED STATEMENT OF CASH FLOWS (INDIRECT METHOD) (UNDER IFRS ADOPTED)

Units: thousands of euros		CURRENT PERIOD 31/12/2021	PREVIOUS PERIOD 31/12/2020
A) CASH FLOWS FROM OPERATING ACTIVITIES (1 + 2 + 3 + 4)	1435	149.441	46.876
1.Profit/(loss) before tax	1405	182.628	72.581
2. Adjustments to profit/(loss)	1410	19.765	21.365
(+) Amortization and depreciation of intangible assets and property, plant and equipment	1411	21.364	19.593
(+/-) Other adjustments to profit/(loss) (net)	1412	(1.599)	1.772
3. Changes in working capital	1415	(64.034)	(63.751)
4. Other cash flows from operating activities:	1420	11.082	16.681
(-) Payment of interest	1421		
(-) Payment of dividends and remuneration of other equity instruments	1430		
(+) Proceeds from dividends	1422		
(+) Proceeds from interest	1423	(4)	(151)
(+/-) Proceeds from/(payments of) corporate income tax	1424	(23.861)	(6.038)
(+/-) Other proceeds from/(payments for) operating activities	1425	34.947	22.870
B) CASH FLOWS FROM INVESTING ACTIVITIES (1+2+3)	1460	(40.839)	(39.625)
1. Payments of investments:	1440	(40.940)	(39.692)
(-) Group companies, associates and business units	1441	(/	(/
(-) Property, plant and equipment, intangible assets and investment property	1442	(40.940)	(39.692)
(-) Other financial assets	1443	(1010-10)	(*****=)
(-) Non-current assets and liabilities classified as held for sale	1459		
(-) Other assets	1444		
2. Proceeds from disinvestments	1450	33	63
(+) Group companies, associates and business units	1451		00
(+) Property, plant and equipment, intangible assets and investment property	1452	33	63
(+) Other financial assets	1453	00	00
(+) Non-current assets and liabilities classified as held for sale	1461		
(+) Other assets	1454		
3. Other cash flows from investing activities	1455	68	4
(+) Proceeds from dividends	1456	00	
(+) Proceeds from interest	1450	68	4
(+/-) Other proceeds from/(payments for) investing activities	1458	00	4
C) CASH FLOWS FROM FINANCING ACTIVITIES (1+2+3+4)	1458	(62.729)	(21.515)
	1490	(36.457)	(21.313)
1. Proceeds from and (payments of) equity instruments:	-	(30.457)	200
	1471		
(-) Amortization	1472	(78.785)	(27.255)
(-) Acquisition	1473	42.328	(37.255) 37.488
(+) Disposal	1474		
2. Proceeds from/ (payments for) financial liability instruments:	1480	(4.852)	(11.749)
(+) Issue	1481	1.340	1.430
(-) Repayment and amortization	1482	(6.192)	(13.179)
3. Payment of dividends and remuneration of other equity instruments	1485	(21.132)	(9.700)
4. Other cash flows from financing activities	1486	(288)	(299)
(-) Payment of interest	1487	(288)	(299)
(+/-) Other proceeds from /(payments for) financing activities	1488		
D) EFFECT OF CHANGES IN EXCHANGE RATES	1492	(= ===	(((00))
E) NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS (A+B+C+D)	1495	45.873	(14.264)
F) CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	1499	53.162	67.426
G) CASH AND CASH EQUIVALENTS AT END OF PERIOD (E+F)	1500	99.035	53.162
COMPONENTS OF CASH AND CASH EQUIVALENTS AT END OF PERIOD		CURRENT PERIOD 31/12/2021	PREVIOUS PERIOD 31/12/2020
(+) Cash in hand and at bank	1550	99.035	53.162
(+) Other financial assets	1552		
() Loss: bank overdrafte renevable on demand	1552		

1553

1600

99.035

53.162



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION 10. DIVIDENDS PAID

		CURREN	F PERIOD	PREVIOU	S PERIOD
		Euros per share (X.XX)	Amount (thousand euros)	Euros per share (X.XX)	Amount (thousand euros)
Ordinary shares	2158	0,38	21.373	0,18	9.818
Other shares (non-voting, redeemable, etc.)	2159				
Total dividends paid	2160	0,38	21.373	0,18	9.818
a) Dividends charged to profit and loss	2155	0,38	21.373	0,18	9.818
a) Dividends charged to reserves or share premium	2156				
c) Dividends in kind	2157				
d) Flexible payment	2154				



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION 11. SEGMENT REPORTING

Units: thousands of euros

Table 1:

		Distribution of net revenue by geographical area						
GEOGRAPHICAL AREA		INDIV	IDUAL	CONSO	LIDATED			
		CURRENT PERIOD PREVIOUS PERIOD CURRENT PERIOD PREVIOUS P						
Domestic market	2210	355.448	353.864	256.698	228.821			
Exports:	2215	154.472	105.560	391.979	191.140			
a) European Union	2216	86.010	76.571	119.632	127.211			
Eurozone	2217	85.853	76.621	119.475	127.261			
Non Eurozone	2218	157	(50)	157	(50)			
c) Other countries	2219	68.462	28.989	272.347	63.929			
TOTAL	2220	509.920	459.424	648.677	419.961			

Table 2:

			CONSO	LIDATED	
			ue from external omers	Profit	or loss
SEGMENTS		CURRENT PERIOD	PREVIOUS PERIOD	CURRENT PERIOD	PREVIOUS PERIOD
Manufacturing	2221	471.788	239.683	136.122	24.602
Marketing	2222	383.975	463.737	44.492	71.138
Other	2223			(40)	(28)
	2224				
	2225				
	2226				
	2227				
	2228				
	2229				
(-)Adjustments between segments	2230	(207.086)	(283.459)	(27.497)	(34.655)
TOTAL	2235	648.677	419.961	153.077	61.057



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION 12. AVERAGE NUMBER OF EMPLOYEES

			IDUAL	CONSOLIDATED		
		CURRENT PERIOD	PREVIOUS PERIOD	CURRENT PERIOD	PREVIOUS PERIOD	
AVERAGE NUMBER OF EMPLOYEES	2295	566	516	1.588	1.364	
Men	2296	248	223	757	639	
Women	2297	318	293	831	725	

IV. SELECTED FINANCIAL INFORMATION 13. COMPENSATION RECEIVED BY DIRECTORS AND SENIOR MANAGEMENT

DIRECTORS:

		Amount (tho	usand euros)
Item of compensation:	CURRENT PERIOD	PREVIOUS PERIOD	
Remuneration for membership of Board or Board committees	2310	576	585
Salaries	2311	803	811
Variable cash remuneration	2312	1.425	403
Share-based remuneration systems	2313	2.520	
Indemnities	2314		
Long-term savings systems	2315	6	24
Other	2316		
TOTAL	2320	5.330	1.823

	Amount (tho	usand euros)	
SENIOR MANAGEMENT:		CURRENT	PREVIOUS
		PERIOD	PERIOD
Total compensation received by senior management	2325	1.706	1.688



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION 14. RELATED-PARTY TRANSACTIONS AND BALANCES (1/2)

		CURRENT PERIOD						
EXPENSES AND INCOME		Significant share- holders	Directors and senior manage- ment	Persons, companies or entities belonging to the group	Other related parties	Total		
1) Finance expenses	2340							
2) Rentals	2343		25		2.030	2.055		
3) Services received	2344							
4) Purchases of goods (finished or in progress)	2345							
5) Other expenses	2348							
EXPENSES (1+2+3+4+5)	2350		25		2.030	2.055		
6) Finance income	2351				22	22		
7) Dividends received	2354							
8) Services provided	2356							
9) Sale of goods (finished or in progress)	2357							
10) Other income	2359							
INCOME (6+7+8+9+10)	2360				22	22		

		CURRENT PERIOD				
OTHER TRANSACTIONS		Significant share- holders	Directors and senior manage- ment	Persons, companies or entities belonging to the group	Other related parties	Total
Financing agreements: loans & capital contributions (lender)	2372					
Financing agreements: loans & capital contributions (borrower)	2375					
Guarantees and guarantee deposits furnished	2381					
Guarantees and guarantee deposits received	2382					
Commitments acquired	2382					
Dividends and other profits distributed	2386	14.044				14.044
Other transactions	2385					

		CURRENT PERIOD				
BALANCES AT END OF PERIOD		Significant share- holders	Directors and senior manage- ment	Persons, companies or entities belonging to the group	Other related parties	Total
1) Customers and trade debtors	2341					
Loans and credits granted	2342			2		2
3) Other amounts receivable	2346					
TOTAL BALANCES RECEIVABLE (1+2+3)	2347			2		2
Suppliers and trade creditors	2352				331	331
5) Loans and credits received	2353					
6) Other payment obligations	2355		1.925	80		2.005
OTHER BALANCES PAYABLE (4+5+6)	2358		1.925	80	331	2.336



Dirección General de Mercados Edison, 4, 28006 Madrid, España (+34) 915 851 500, www.cnmv.es

LABORATORIOS FARMACEUTICOS ROVI, S.A.

IV. SELECTED FINANCIAL INFORMATION 14. RELATED-PARTY TRANSACTIONS AND BALANCES (2/2)

RELATED-PARTY TRANSACTIONS		PREVIOUS PERIOD						
EXPENSES AND INCOME		Significant share- holders	Directors and senior manage- ment	Persons, companies or entities belonging to the group	Other related parties	Total		
1) Finance expenses	6340							
2) Rentals	6343		25		2.033	2.058		
3) Services received	6344							
4) Purchases of goods (finished or in progress)	6345							
5) Other expenses	6348							
EXPENSES (1+2+3+4+5)	6350		25		2.033	2.058		
6) Finance income	6351				22	22		
7) Dividends received	6354							
8) Services provided	6356							
9) Sale of goods (finished or in progress)	6357							
10) Other income	6359							
INCOME (6+7+8+9+10)	6360				22	22		

		PREVIOUS PERIOD				
OTHER TRANSACTIONS		Significant share- holders	Directors and senior manage- ment	Persons, companies or entities belonging to the group	Other related parties	Total
Financing agreements: loans & capital contributions (lender)	6372					
Financing agreements: loans & capital contributions (borrower)	6375					
Guarantees and guarantee deposits furnished	6381					
Guarantees and guarantee deposits received	6382					
Commitments acquired	6382					
Dividends and other profits distributed	6386	6.743				6.743
Other transactions	6385					

		PREVIOUS PERIOD				
BALANCES AT END OF PERIOD		Significant share- holders	Directors and senior manage- ment	Persons, companies or entities belonging to the group	Other related parties	Total
1) Customers and trade debtors	6341			6		6
Loans and credits granted	6342			46		46
3) Other amounts receivable	6346		44			44
TOTAL BALANCES RECEIVABLE (1+2+3)	6347		44	52		96
Suppliers and trade creditors	6352				350	350
5) Loans and credits received	6353					
6) Other payment obligations	6355		1.640	80		1.720
OTHER BALANCES PAYABLE (4+5+6)	6358		1.640	80	350	2.070